|
Myriad Genetics, Inc. (MYGN) which develops and commercializes genes involved in major common diseases including cancer, cardiovascular disease, and central nervous system disorders scored a new FusionIQ short squeeze yesterday as shares which have 25 percent of their float short shot up aggressively on close to 2 times its normal 21-day average volume.
Additionally, MYGN shares also scored a new FusionIQ timing BUY signal yesterday.
|